Epirus Switzerland, which will merge with Zalicus Inc. (Nasdaq: ZLCS), reported positive results from a Phase 3 study of its active rheumatoid arthritis treatment BOW015. Zalicus stock leaped 43 cents to close at $1.51.
Zalicus soars on Epirus Switzerland's results
June 12, 2014 at 19:02 PM EDT
